UK CMA Clears PSKY/WBD Merger
UK regulator clears merger deal
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
11 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Ford Motor Stock Dips Friday: What's Driving the Post-Earnings Reset?
Ford Motor Co. (NYSE: F ) shares are trading lower on Friday as investors weigh a mixed earnings follow-through and fresh analyst commentary on pricing and product mix. Ford Motor shares are under pressure. Why is F stock retreating? What Is Driving Ford’s Earnings Outlook? Ford’s latest update showed adjusted EPS of 4
AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat
AbbVie Inc. (NYSE: ABBV ) shares are retreating Friday as a modest reduction to full-year adjusted EPS guidance that pushed the midpoint beneath the analyst target proved enough to sour the market’s mood. Here’s what you should know. AbbVie shares are under pressure. Why are ABBV shares declining? A Guidance Trim Overs
AbbVie Q2 2026 Earnings
Adj EPS $3.65 (est $3.61) - Net Rev. $16.99B (est $16.77B) - Skyrizi Rev $5.51B (est $5.43B) - RINVOQ Rev. $2.53B (est $2.48B) - Humira Rev $756M (est $734.1M) - Imbruvica $532M (est $563.2M) - Sees FY Adj EPS $13.87 To $14.07, Saw $13.91 To $14.11 - Yr View Incl Unfavourable Impact Of $0.58/SHR ON IPR&D - Yr View Incl
ABBV AbbVie Inc RESULTS: Q2, Q2 global Skyrizi REV $5.505B, Q2 global Rinvoq REV $2.525B, Q2 global Humira REV $756M, Q2 ADJ EPS $3.65 vs. E
ABBV AbbVie Inc RESULTS: Q2, Q2 global Skyrizi REV $5.505B, Q2 global Rinvoq REV $2.525B, Q2 global Humira REV $756M, Q2 ADJ EPS $3.65 vs. EST $3.60, Q2 REV $16.990B vs. EST $16.765B, Abbvie Inc Earnings Notes:, Q2 results include an unfavorable impact of $0.17/share related to acquired ipr&d and milestones expense, FY
Abbvie Q2 2026 Earnings
Abbvie Q2 2026 Earnings
Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says
() -- Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday. Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) rem
AbbVie's Q2 Results Expected to be Inline With Expectations, RBC Says
() -- AbbVie's (ABBV) Q2 financial results are expected to be in line with expectations, RBC Capital Markets analysts said in a Friday note. The company is scheduled to report its Q2 financial results on July 31. Analysts said sentiment on AbbVie has changed significantly, especially after the recent Apogee deal, which
Abbvie Q2 2026 Earnings
Abbvie Q2 2026 Earnings
AbbVie says Q2 EPS to include unfavorable impact of 17c
In a regulatory filing, AbbVie said that reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2026 are expected to include acquired IPR&D and milestones expense of $291 million on a pre-tax basis, representing an unfavorable impact of $0.17 to both GAAP diluted earnings per share and adjusted
AbbVie Sees FY2026 Adj. Diluted EPS $13.91-$14.11 Including Q2 IPR&D Expense - SEC Filing
* Sees Q2 Adj. Diluted EPS $3.57-$3.61 Including IPR&D Expense * Q2 Includes $291M Bought IPR&D Expense, Impacting GAAP And Adj. Diluted EPS By $0.17